Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Vigil Neuroscience, Inc.

Get SEC filing alerts via email and in your feed for Vigil Neuroscience, Inc.

VIGL

Vigil Neuroscience, Inc.

About Vigil Neuroscience, Inc.

Vigil Neuroscience is a biotech company developing microglia-targeted, disease-modifying therapeutics for neurodegenerative diseases. Its pipeline includes monoclonal antibodies and small molecules aimed at activating TREM2, a key microglial receptor. Focused on rare conditions like ALSP and common diseases such as Alzheimer's, Vigil leverages precision medicine, biomarkers, and stakeholder engagement to address unmet medical needs in CNS health.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Vigil Neuroscience, Inc.

1
1
Vigil Neuroscience, Inc. Vigil Neuroscience Reports $26.7 Million Net Loss in Q2 2025, Plans Merger with Sanofi

Via official filing (AI summary) | 11 months ago | 0 comments

2
1
Vigil Neuroscience, Inc. Vigil Neuroscience Reports $22.4 Million Net Loss in Q1 2025, Focuses on Clinical Development

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
Vigil Neuroscience, Inc. Vigil Neuroscience Reports $84.3 Million Net Loss for 2024, Highlights Clinical Trial Developments

Via official filing (AI summary) | over 1 year ago | 0 comments

4
1
Vigil Neuroscience, Inc. Vigil Neuroscience Reports Q3 Financial Results, Net Loss of $19.3M

Via official filing (AI summary) | over 1 year ago | 0 comments